SCHEMBL4035375

SCHEMBL4035375

N#Cc1ccccc1NCCC(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
HPGD P15428 3/20 0.58
HSD17B10 Q99714 3/20 0.58
KDM4E B2RXH2 5/20 0.56
TSHR P16473 2/20 0.56
GAA P10253 4/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NSD2 O96028 1/20 0.50
POLB P06746 1/20 0.50
BLM P54132 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 3/20 0.49
MAPT P10636 1/20 0.49
AKR1C3 P42330 1/20 0.49
AKR1C2 P52895 1/20 0.49
AKR1C1 Q04828 1/20 0.49
CXCR2 P25025 1/20 0.43
GLA P06280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5346877 0.83 KDM4E (0.59) ALDH1A1HPGDHSD17B10KDM4ETSHR
SCHEMBL4837963 0.83 GAA (0.55) ALDH1A1HPGDHSD17B10KDM4ETSHR
SCHEMBL7528112 0.79 KDM4E (0.58) ALDH1A1HPGDHSD17B10KDM4ETSHR
SCHEMBL21268468 0.78 GAA (0.56) ALDH1A1HPGDHSD17B10KDM4ETSHR
SCHEMBL7521970 0.77 KDM4E (0.61) ALDH1A1HPGDHSD17B10KDM4ETSHR
SCHEMBL7824258 0.76 TSHR (0.74) ALDH1A1KDM4ETSHRGAAMEN1
SCHEMBL7522731 0.76 KDM4E (0.54) ALDH1A1HPGDHSD17B10KDM4ETSHR
SCHEMBL3207752 0.75 ALDH1A1 (0.66) ALDH1A1HPGDHSD17B10KDM4EGAA
SCHEMBL2122821 0.75 TSHR (0.58) ALDH1A1HPGDHSD17B10KDM4ETSHR
SCHEMBL30317451 0.75 TSHR (0.58) ALDH1A1HPGDHSD17B10KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102746214-A Novel indoline compounds FOURNIER LAB SA 2012-10-24 CN disclosed
EP-1885695-B1 INDOLINE COMPOUNDS FOURNIER LAB SA (FR) 2009-02-25 EP disclosed
US-7465811-B2 Indoline compounds LABORATOIRES FOURNIER S.A. (FR) 2008-12-16 US disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 US disclosed
CN-101184731-A Indoline compounds FOURNIER LAB SA (FR) 2008-05-21 CN disclosed
CN-1198746-A Tricyclic benzazepine * vasopressin antagonists AMERICAN CYANAMID CO (US) 1998-11-11 CN disclosed
CN-1178532-A Tricyclic vasopressin antagonists AMERICAN CYANAMID CO (US) 1998-04-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119465-A1 Novel Indoline Compounds GPR119, INSR, IRS1 ALDH1A1 1819/4885HPGD 3316/4885HSD17B10 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.